Comparison of Beers criteria and EU(7) potentially inappropriate medications list for the potentially inappropriate medications in Indian elderly inpatients

Manoj H. Thummar¹, Tejas K. Patel²*, Varsha Y. Godbole³, Manoj Kumar Saurabh²

ABSTRACT

Background: Use of inappropriate medication is an important problem in present geriatric clinical practice. No specific potentially inappropriate medications (PIM) tools are available considering the availability of drugs in India. Aim and objective were to assess prevalence and pattern of potentially inappropriate medication (PIM) use in elderly inpatients by updated Beers criteria 2015 and EU(7) PIM list 2015.

Methods: This cross-sectional study was carried out on medical records of elderly patients (≥65 yrs) admitted in the internal medicine wards and intensive care units (ICU) over a period of 6 weeks. The medications were evaluated for the PIM use as per Beers criteria and EU(7) PIM list.

Results: A total of 225 patients (mean age- 71.48 yrs) were admitted in internal medicine wards and ICU during study period. Total 184 PIM belonged to 33 different medications were used during study period. The prevalence of PIM in internal medicine wards and ICUs were 51.96% and 57.14%, respectively. The prevalence of PIM was significantly higher with the EU(7) PIM list than Beers criteria (49.77% vs. 21.77%) [p<0.0001]. The commonly prescribed PIM were dextromethorphan (13.33%), ranitidine (11.11%) and glipizide (10.22%).

Conclusions: Elderly patients frequently receive PIM. EU(7) PIM list identifies more PIM among elderly inpatients than Beers criteria.

Keywords: Beers criteria, EU(7) PIM list, Elderly, Internal medicine wards, Intensive care units, Potentially inappropriate medications

INTRODUCTION

An elderly person receives more drugs than other age groups due to multiple comorbidities. Moreover, age related pharmacokinetic and pharmacodynamic changes prone them for the adverse drug reactions.¹ Earlier systematic reviews observed elderly patients are at high risk of having adverse drug reactions.² ³ An inappropriate medication prescribed is the major problem in present clinical practices.⁴ A potentially inappropriate medication (PIM) refers to prescription of drugs carrying risks outweighing the expected clinical benefits, especially when there is evidence for an equally or more effective and safer alternative medication.⁵ The use of PIM is associated with the risk of adverse drug reactions and adverse drug events.⁶ An earlier systematic review observed the use of PIM is associated with higher rates of hospitalisation, health care costs and quality of life problems.⁷ It is important to identify and reduce the PIM use in an elderly population.

There are various tools available to evaluate PIM use in an elderly population.⁸-¹¹ The Beers criteria have been widely used to identify and monitor PIM use in elderly patients in
internal medicine wards and ICU hospitalisation. The Beers criteria have been updated recently in 2015 by 13-member interdisciplinary expert panel using modified Delphi method. The important changes in the new version are the lists of drugs to be avoided or dose adjustment based on the renal function and drug-drug interactions associated with harms in an elderly population. Only one earlier Indian internal medicine studies explored the PIM use as per the updated version of the Beers criteria. However, it did not compare its effectiveness as a screening tool with other criteria. Another recent criterion is an European Union list of potentially inappropriate medications [EU(7) PIM list]: a list of potentially inappropriate medications for older people consented by experts from seven European countries. EU(7) PIM list suggests dose adjustments and special considerations when PIM to be use and alternative drugs for PIM. It has not been explored in India. No such specific PIM tools are available considering the availability of drugs in India. So, this study was designed to assess the use of PIM in elderly patients in internal medicine wards and medical ICU in a tertiary care teaching hospital of India using such two recently introduced criteria- Updated Beers Criteria (2015) and EU(7) PIM list (2015).

METHODS

This cross-sectional study was carried out after obtaining the permission from the Institutional Human Ethic Committee (IHEC). The inpatient records were retrospectively collected after the IHEC permission. The consent waiver was obtained from the IHEC.

Study population

All elderly patients ≥ 65 years of age group admitted in the internal medicine wards and medical ICUs of GMERS General Hospital, Gotri between 1st July 2017 and 14th August, 2017.

Selection criteria

All elderly inpatients admitted for ≥24 hrs and received at least one prescribed medication were included in the study. Patients only admitted for observation were excluded from the analysis.

Data were collected in a case record form about patient’s demographic details, diagnoses, hospital stay duration, treatment, related investigations and outcome. All prescribed drugs were labelled according to World Health Organization- anatomical therapeutic chemical (WHO-ATC) classification. The prescribed drugs were screened for the PIM (if present) using the updated Beer’s Criteria (2015) and EU(7) PIM list (2015).

Outcome measures

Primary outcome variable was to estimate prevalence of PIM in the elderly patients as per updated Beer’s Criteria (2015), EU(7) PIM list (2015) and overall PIM prevalence. We used a total number of elderly patients receiving at least one PIM as numerator and total number of elderly patients as a denominator to estimate prevalence as per updated Beer’s Criteria (2015) and EU(7) PIM list (2015). In case of the overall PIM prevalence, total number of elderly patients receiving at least one PIM identified by any one of the EU(7) PIM list and Beers criteria was considered as numerator.

Secondary outcome variables were to compare updated Beer’s Criteria (2015) and EU(7) PIM list (2015) for the average number of PIM per patient, total number of PIM identified, WHO-ATC drug class system, underlying disorders in which PIM was used. Other secondary outcome variables screened as per Beer’s criteria were WHO-ATC drug class pattern of PIM for the ‘potential drug-disease or drug-syndrome interaction’ that may exacerbate the disease or syndrome, drugs to be used with caution, clinically important ‘drug-drug interactions’ to be avoided, drug to be avoided or dosage to be reduced in the presence of renal dysfunction and use of drugs with strong anticholinergic property. As per EU(7) PIM list (2015), ‘questionable PIM’ were also screened. The ‘questionable PIM’ means those drugs on which no consensus among expert panellist of EU(7) PIM group was reached on the appropriateness of use in the elderly.

Data analysis

All data were extracted into Microsoft excel sheet and cross-checked for the accuracy. We used percentage to present the data on prevalence of PIM, commonly used PIM, common diseases in which PIM was prescribed. We used mean (standard deviation-SD) to present the data of age, total number of drugs prescribed per patient and number of PIM prescribed per patient. We compared continuous data using unpaired t-test and categorical data using Chi-square test/Fisher’s exact test. All statistical analysis was performed using GraphPad Instat demo version (San Diego, CA 92108, USA). P < 0.05 was considered as statistically significant difference.

RESULTS

General characteristics of patients

Out of 1603 patients admitted in Internal medicine wards and ICU during study period, 258 patients were geriatrics. Thirty-three patients were excluded due to <24 hr hospital stay. A total of 225 patients were included in this study. Male patients were 118 and female patients were 107 (M/F ratio=1:1.10). Twenty-one patients were admitted in ICUs. The mean age of the patients was 71.48 years (SD-6.42) with the age range of 65 to 92 years. The average number of drugs prescribed per patient was 11.95 (SD-4.28; range:4-12).

The most frequent diagnosis of study population admitted in wards were chronic obstructive pulmonary disease
(COPD)- 52 (25.49%), ischaemic heart disease (IHD)- 36 (17.64%), cerebrovascular stroke (CV stroke)- 27 (12%), dilated cardiomyopathy (DCM)- 18 (8.82%), lower respiratory tract infection (LRTI)- 10 (4.90%), while ICU patients were admitted mainly for COPD- 7 (33.33%), IHD- 5 (23.80%) and pleural effusion- 4 (16.66%). The commonly observed comorbidities were hypertension- 66 (29.33%) and diabetes mellitus (DM)- 51 (22.66%) (Table 1). The clinical diagnoses and co-morbidities were not significantly differ in patients receiving PIM as per EU(7) PIM list and Beers criteria.

### Table 1: Demography and clinical characteristics of study participants, and their comparison among patients receiving PIM as per EU(7) PIM list and Beers criteria.

| Variables                  | All patients n=225 | Patients receiving PIM as per EU(7) PIM list n=112 | Patients receiving PIM as per Beers criteria n=49 | P values (Beers criteria vs. EU(7) PIM list) |
|----------------------------|--------------------|----------------------------------------------------|---------------------------------------------------|---------------------------------------------|
| Age, years Mean (SD)       | 71.48 (6.42)       | 72.10 (6.58)                                       | 71.12 (6.67)                                      | 0.38                                        |
| Male gender n (%)          | 118 (52.44%)       | 54 (48.21%)                                        | 23 (46.93%)                                       | 0.88                                        |
| Prescribed medications per patient Mean (SD) | 11.95 (4.28)       | 13.29 (4.28)                                       | 14.26 (5.03)                                      | 0.21                                        |
| PIM prescribed per patient Mean (SD) | 0.81 (1.04)        | 0.71 (0.8)                                         | 0.28 (0.61)                                       | 0.001                                       |
| PIM prevalence n (%)       | 118 (52.44%)       | 112 (49.77%)                                       | 49 (21.77%)                                       | <0.0001                                     |
| Clinical diagnosis n (%)   |                   |                                                   |                                                  |                                             |
| COPD                       | 59 (26.22%)        | 26 (23.12)                                         | 08 (16.32)                                        | 0.44                                        |
| IHD                        | 41 (18.22%)        | 21 (18.75)                                         | 08 (16.32)                                        | 0.89                                        |
| CV stroke                  | 27 (12.00%)        | 15 (13.39)                                         | 06 (12.24)                                        | 0.84                                        |
| DCM                        | 19 (8.44%)         | 17 (15.18)                                         | 12 (24.49)                                        | 0.23                                        |
| LRTI                       | 11 (4.88%)         | 06 (5.35)                                          | 02 (4.08)                                         | 1.00                                        |

p-value by unpaired t-test for continuous data and Chi-square test/Fisher’s exact test for categorical data. PIM - Potentially inappropriate medications; COPD- chronic obstructive pulmonary disease; IHD- ischaemic heart disease; CV - cerebrovascular; DCM - dilated cardiomyopathy; LRTI - lower respiratory tract infection.

**PIM prevalence**

Overall use of at least one PIM was identified in 118 patients (52.44%). The prevalence of PIM in internal medicine wards and ICUs were 51.96, and 57.14 percent, respectively. EU(7) PIM list and Beers criteria suggested 86.94% and 34.23% of total PIM, respectively. EU(7) PIM list suggested significantly higher number of patients receiving at least one PIM as compared to Beers criteria [112 vs. 29, p < 0.0001]. The prevalence of PIM using EU(7) PIM list and Beers criteria were 49.77 and 21.77 percent, respectively. The average number of PIM prescribed per patient was also significantly higher as per EU(7) PIM list than Beers criteria (0.71 vs. 0.28, p=0.001) (Table 1).

**Use pattern of PIM (Beers criteria versus EU(7) PIM list)**

A total of 184 PIM belonged to 33 different medications were used in study population. EU(7) PIM list suggested 160 (86.94%) PIM of 26 different medications. Beers criteria suggested 63 (34.23%) PIM of 15 different medications. Only a total of 39 (21.90%) PIM of 8 different medications were found present in both the list. In case of internal medicine wards, Beers criteria suggested 58 PIM of 15 different medications and EU(7) PIM list identified 145 PIM of 25 different medications use. While in case of ICU, use of 5 PIM of different 5 medications were suggested by Beers criteria and 16 PIM of 9 different medications as per EU(7) PIM list.

The PIM, present in both lists, belonged to NSAIDs (autacoids), anticholinergics (autonomic nervous system), cardiac glycosides (cardiovascular system), antihistaminics, central alpha blocker. Additionally PIM identified by EU(7) PIM list belongs to cough suppressant (respiratory system), drugs for peptic ulcer and GERD (gastrointestinal system), blood glucose lowering agent (endocrine system) and potassium sparing diuretic. Common disorders in which PIM use were observed were...
COPD- 27(12%), IHD- 23(10.22%), DCM-17(7.55%), CV stroke- 12(5.33%), LRTI- 6(2.66%). The commonly involved systems were respiratory- 94(41.77%), cardiovascular- 91(40.44%) and central nervous system- 37(16.44%).

Table 2: Potentially inappropriate medications (PIM) identified by using the Beers criteria 2015 and the EU(7) PIM list 2015.

| Groups                          | Drugs                   | ATC code     | Number of patient prescribed in wards (%) | Number of patient prescribed in ICU (%) |
|--------------------------------|-------------------------|--------------|-------------------------------------------|-----------------------------------------|
| Gastrointestinal tract         | Ranitidine²             | A02BA02      | 29 (14.21)                                | 08 (38.09)                              |
|                                | Famotidine²             | A02BA03      | 24 (11.76)                                | 01 (4.76)                               |
| Drugs for peptic ulcer and GERD # | Liquid paraffin²       | A06AA01      | 02 (0.98)                                 | 03 (14.28)                              |
|                                | Sodium picosulfate²    | A06AB08      | 01 (0.49)                                 | 02 (9.52)                               |
| Laxatives                      | Metoclopramide¹,²       | A03FA01      | 02 (0.98)                                 | 01 (4.76)                               |
| Respiratory system             |                         |              |                                           |                                         |
|                                | Dextromethorhan²        | R05DA09      | 27 (13.23)                                | 03 (14.28)                              |
| Cough and cold preparation     |                         |              |                                           |                                         |
| Adrenergics for systemic use   | Terbutaline(oral)²     | R03CC03      | 01 (0.49)                                 | -                                       |
| Cardiovascular system          |                         |              |                                           |                                         |
|                                | Digoxin¹,²              | C01AA05      | 10 (4.90)                                 | -                                       |
|                                | Clonidine¹,²            | C02AC01      | 03 (1.47)                                 | 01 (4.76)                               |
|                                | Amiodarone¹,²           | C01BD01      | 01 (0.49)                                 | -                                       |
|                                | Ixivabradine²           | C01EB17      | 01 (0.49)                                 | -                                       |
|                                | Spironolactone²         | C03DA01      | 10 (4.90)                                 | 03 (14.28)                              |
| Endocrine system               |                         |              |                                           |                                         |
|                                | Glipizide²              | A10BB07      | 23 (11.27)                                | -                                       |
|                                | Glimepiride²            | A10BB12      | 03 (1.47)                                 | -                                       |
|                                | Pioglitazone²           | A10BG03      | 01 (0.49)                                 | -                                       |
| Central nervous system         |                         |              |                                           |                                         |
|                                | Phenytoin²              | N03AB02      | 05 (2.45)                                 | 01 (4.76)                               |
|                                | Lorazepam¹*             | N05BA06      | 03 (1.47)                                 | -                                       |
|                                | Alprazolam¹*            | N05BA12      | 02 (0.98)                                 | -                                       |
|                                | Amitriptyline¹*         | N06AA09      | 02 (0.98)                                 | -                                       |
|                                | Prochlorperazine²       | N05AB04      | 02 (0.98)                                 | -                                       |
|                                | Haloperidol¹,²          | N05AD01      | 02 (0.98)                                 | -                                       |
|                                | Olanzapine¹*            | N05AH03      | 01 (0.49)                                 | -                                       |
| Psychostimulant, agent for ADHD, nootropics | Piracetam² | N06BX03      | 01 (0.49)                                 | -                                       |
|                                | Tizanidine²             | M03BX02      | 01 (0.49)                                 | -                                       |
|                                | Tramadol¹               | N02AX02      | 03 (1.47)                                 | -                                       |
| Opioids                        |                         |              |                                           |                                         |
| Anticholinergics               |                         |              |                                           |                                         |
| First generation antihistaminics | Chlorpheniramine¹,²    | R06AB04      | 07 (3.43)                                 | -                                       |
|                                | Promethazine¹           | R06AD02      | 01 (0.49)                                 | -                                       |
|                                | Dicyclomine¹            | A03AA07      | 10 (4.90)                                 | 01 (4.76)                               |
|                                | Atropine¹               | A03BA01      | 01 (0.49)                                 | 01 (4.76)                               |
|                                | Hyosine¹,²              | A03BA03      | 02 (0.98)                                 | -                                       |
| Non- steroidal anti inflammatory drugs (NSAIDs) | Diclofenac¹,² | M01AB05      | 11 (5.39)                                 | 01 (4.76)                               |
|                                | Aceclofenac²            | M01AB16      | 01 (0.49)                                 | -                                       |
| Antibacterial for systemic use |                         |              | 01 (0.49)                                 | -                                       |
| Quinolone antibacterials        | Ofloxacin²              | J01MA01      | 01 (0.49)                                 | -                                       |

¹as per Beers criteria; ²as per EU(7) PIM list; ICU - intensive care unit; ATC - Anatomical therapeutic classification; ADHD- Attention deficit hyperactivity disorder; GERD- Gastroesophageal reflux disease; ¹¹ Lorazepam, Alprazolam Amitriptyline Olanzapine and Metoclopramide were used in appropriate doses as per for elderly EU(7) PIM list, thus only included in Beers criteria.
Table 3: Questionable PIM as per EU(7) PIM list.

| Drugs                              | ATC Code     | Total cases in wards (%) | Total cases in ICU (%) |
|------------------------------------|--------------|--------------------------|------------------------|
| Ipratropium bromide (inhaled)      | R03BB01      | 72 (35.29)               | 09(42.85)              |
| Amlodipine                         | C08CA01      | 57 (27.94)               | 03(14.28)              |
| Aspirin low dose in primary prevention of cardiovascular disease | B01AC06      | 20 (9.80)                | 03(14.28)              |
| Levofloxacin                       | J01MA12      | 16 (7.84)                | 01(4.76)               |
| Ciprofloxin                        | J01MA02      | 15 (6.66)                | -                      |
| Metformin (>2x850mg)               | A10BA02      | 03 (1.33)                | -                      |
| Gabapentin                         | N03AX12      | 03 (1.33)                | -                      |
| Pregabalin                         | N03AX16      | 03 (1.33)                | -                      |
| Carvedilol                         | C07AG02      | 02 (0.88)                | -                      |
| Tamsulosin                         | G04CA02      | 02 (0.88)                | -                      |

PIM - Potentially inappropriate medications; ATC - Anatomical therapeutic classification; ICU - intensive care unit.

The commonly prescribed PIM were dextromethorphan (13.33%), ramitidine (11.11%), glipizide (10.22%), spironolactone (5.77%) and diclofenac (5.33%). All were included in EU(7) PIM list. Beers criteria suggested diclofenac only. The commonly prescribed PIM as per Beers criteria were diclofenac (5.33%), dicloclam (4.88%), digoxin (4.44%), chlorpheniramine (3.11%) and clonidine (1.77%). All of them were present in EU(7) PIM list except dicyclomine. Lorazepam, alprazolam, amitriptyline, olanzapine and metoclopramide (2 patients) were considered inappropriate as per Beers criteria. They were not considered PIM as per EU(7) PIM list due to their appropriate dosage selection (Table 2).

Use of ‘questionable PIM’ as per EU(7) PIM list

Total number of the ‘questionable PIM’ identified by EU(7) PIM list were 209 of different 10 medications. As shown in Table 3, commonly used medications of this category were ipratropium bromide (inhaled) (36%), amiodipine (26.66%), aspirin low dose in primary prevention of cardiovascular disease (10.22%), levofloxacin (7.55%) and ciprofloxacin (6.66%).

Drug to be used with caution in elderly (Beers criteria)

As shown in Table 4, commonly identified drugs to be used with caution were furosemide (14.22%), spironolactone (3.55%), torasemide (0.88%). All three diuretics used in patients having hyponatremia.

Drug-disease and drug-drug interaction (Beers criteria)

A total of 8 ‘drug-disease or drug-syndrome’ interactions were identified that may exacerbate the disease or syndrome. Those were use of diltiazem in patients of heart failure; use of haloperidol and olanzapine (antipsychotics), lorazepam (benzodiazepines), hydrocortisone and budesonide (corticosteroids), and ranitidine (H2: receptor antagonist) in patients of delirium; and use of chlorpheniramine (strong anticholinergic drug) in patient of benign prostatic hyperplasia. The potentially clinically important ‘drug- drug interactions’ that should be avoided in older adults were the concomitant use of drugs having anticholinergic (3.11%) actions (Table 5).

Use of drugs according to renal functions (Beers criteria)

The most commonly used non-anti-infective medications that should be avoided or their dosage reduced as per kidney function in older adults was ranitidine- 38(16.88%) with CrCL of <50 mL/min. Other drugs were spironolactone- 1(0.44%) and enoxaparin-1(0.44%) with CrCL of <30 mL/min.

Table 4: PIM to be used with cautions in older adults as per Beers criteria.

| Groups                  | Drugs (ATC)             | Rationale          | Total cases in wards (%) | Total cases in ICU (%) |
|-------------------------|-------------------------|---------------------|--------------------------|------------------------|
| Diuretics               | Furosemide(C03CA01)     | Hyponatremia        | 24 (11.76)               | 08 (38.09)             |
|                         | Spironolactone(C03DA01) |                     | 07 (3.43)                | 01 (4.76)              |
|                         | Torasemide(C03CA04)     |                     | 01 (0.49)                | 01 (4.76)              |
|                         | Chlorthalidone(C03BA04) |                     | 01 (0.49)                | -                      |
| Antipsychotics          | Haloperidol(N05AD01)    |                     | 01 (0.49)                | -                      |
|                         | Olanzapine(N05AH03)     |                     | 01 (0.49)                | -                      |
| SSRIs                   | Fluoxetine(N06AB03)     | Lack of evidence of  | 01 (0.49)                | -                      |
|                         |                         | benefit versus risk | -                        | 01 (4.76)              |
|                         | Amitriptyline(N06AA09)  |                     |                          |                        |
| Platelet aggregation inhibitor | Aspirin(B01AC06) for primary prevention of cardiac events in adults aged≥80 | | | |

PIM - Potentially inappropriate medications; ATC - Anatomical therapeutic classification; ICU - intensive care unit; SSRIs- Selective serotonin reuptake inhibitors; TCAs- Tricyclic antidepressants
### Table 5: Clinically important non-anti-infective drug-drug interactions that should be avoided in older adults as per Beers criteria.

| Object drug class | Interaction drug class | Total cases in wards (%) | Total cases in ICU (%) |
|-------------------|------------------------|--------------------------|------------------------|
| Anticholinergic    | Anticholinergic         | 07 (3.43)                | -                      |
| Dicyclomine       | Chlorpheniramine, Hyoscine, Amitriptyline, Promethazine (1 each) | 04 (1.96)                | -                      |
| Ipratropium bromide(inhaled) | Chlorpheniramine, Dicyclomine, Olanzapine (1 each) | 03 (1.47)                | -                      |
| Benzodiazepines   | ≥2 other CNS active drugs | 02 (0.98)                | -                      |
| Lorazepam         | Haloperidol+ Olanzapine, Haloperidol + Promethazine (1 each) | 02 (0.98)                | -                      |
| Others            |                        |                          |                        |
| Tamsulosin        | Furosemide             | 01 (0.49)                | -                      |
| Hydrocortisone    | Diclofenac             | 01 (0.49)                | 01 (0.49)              |

ICU - intensive care unit

**Drugs with strong anticholinergic properties (Beers criteria)**

Drugs with strong anticholinergic were dicyclomine-11(4.88%), chlorpheniramine-6(2.66%), amitriptyline-3(1.33%), atropine(iv)-2(0.88%), hyoscine(iv)-2(0.88%), prochlorperazine-2(0.88%), promethazine-1(0.44%) and olanzapine-1(0.44%).

**DISCUSSION**

This study was designed to assess prevalence of PIM and to compare two PIM criteria in elderly patients admitted in a tertiary care teaching hospital in India. Our findings suggest PIM is an important area of concern for the drug use in elderly Indian inpatients. EU(7) PIM list helped to identify more number of PIM in this study population than Beers criteria.

The prevalence of PIM was significantly varied by two fold between Beers criteria (21.77%) and EU(7) PIM list (49.77%). This observed difference could be due to common use of drugs like dextromethorphan, ranitidine, glipizide and spironolactone in this set up. These drugs were considered PIM as per EU (7) list but not included in Beers criteria. The EU(7) PIM list includes most of the PIM present in Beers criteria. This suggests more sensitivity of EU(7) PIM list to detect PIM than Beers criteria. EU(7) PIM list also offers advantages in terms of dosage adjustment/titration, appropriate indications and use of alternative drugs. The Beers criteria tool offers an easy evaluation of drug-disease, drug-drug interactions and drugs to be used cautiously in the presence of altered renal functions.

Dextromethorphan is considered PIM due to its doubtful efficacy. Ranitidine is considered PIM due to availability of better alternative (PPI) and evidence of uncommon but significant adverse effects like lethargy, somnolence and disorientation with its use. This is particularly problematic in older patients with impaired renal function with the dose of >150mg/24h(oral) or 50mg/24h(iv). Its dose should be reduced in patients with altered renal function (<50CrCL/min.). The preference of ranitidine over PPI seen in this setup could be due to economic reason. Ranitidine is available through Government supply in this set up. The literature suggests glipizide is comparable to metformin (1.82% decrease in HbA1c vs 2%) in type 2 DM patients. In this study, glipizide was considered PIM due to inappropriate dose titration and the risk of protracted hypoglycaemia with its use. EU(7) PIM list suggest metformin or gliclazide as an alternative to glipizide. Spironolactone have higher risk of hyperkalaemia and hyponatremia, especially if doses ≥25mg/d. It requires monitoring of the serum Na+ to adjust the dose and should be avoided in patients with CrCl<30mL/min. Recent study suggest that higher dose of the spironolactone was well tolerated without any improvement in primary or the secondary outcomes. Diclofenac is associated 2.5 folds higher risk of gastrointestinal bleeding than paracetamol and ibuprofen. It shares equal risk of gastrointestinal bleeding with naproxen. To reduce gastrointestinal risk, it should be started with low dose (50 mg/d) with concomitant PPIs. The alternatives are paracetamol, ibuprofen (≤3x400mg/d or for a period shorter than 1 week), naproxen (≤2x250mg/d or for a period shorter than 1 week). The other problem with diclofenac use in elderly is 1.2 to 2 folds higher risk of cardiovascular events than paracetamol and ibuprofen. Dicyclomine was considered PIM due to its strong anticholinergic action and uncertain effectiveness as antispasmodic. It also interacts with the other anticholinergics that increases the risk of cognitive decline.

In this study, commonly used ‘questionable PIM’ were ipratropium bromide, amiodipine and aspirin. Inhaled anticholinergics effectively control the COPD exacerbations and improves the quality of life.
However, they increase the risk of cardiovascular morbidity and mortality.\textsuperscript{28,29} They require cautious use in patients having cardiac disorders. Amlodipine is well tolerated and effective antihypertensive.\textsuperscript{30} It can be prescribed in the comorbid conditions of hypertension.\textsuperscript{31} However, literature suggests variable effect of amlodipine in patients of heart failure.\textsuperscript{32} Recently one study suggest low dose aspirin do not effective as primary prevention of cardiovascular diseases and increases the risk of major haemorrhage.\textsuperscript{33}

The most commonly used drug belonged to the category of ‘drug to be used with caution’ was diuretics. They increases the risk of hospitalizations due to risk of hyponatremia, hypokalaemia and decrease in the GFR.\textsuperscript{20,34} Antipsychotics (typical and atypical) increases the risk of the hyponatremia and requires serum Na\textsuperscript+ level monitoring.\textsuperscript{35,36} Antidepressants selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCA) are also associated with the hyponatremia, but more with SSRI compared to the TCA.\textsuperscript{37}

In case of drug-disease interaction, diltiazem (non-dihydropyridine CCB) increases the risk of hospitalization in heart failure patients.\textsuperscript{38} It may worsen constipation and increases the risk of bradycardia.\textsuperscript{16} In a patient of delirium, antipsychotics increase the risk of confusion, hallucinations, delusions; prolongation of the QT interval and metabolic complications; benzodiazepines itself increases the risk of delirium, confusion, agitation and paradoxical excitation, respiratory depression.\textsuperscript{39-42} Ranitidine and corticosteroids have low to moderate risk for the occurrence of delirium. Prescription of the strong anticholinergics may decrease the urinary flow and aggravate the symptoms.\textsuperscript{20} Anticholinergics increases the risk of cognitive decline and the dementia in elderly patients.\textsuperscript{20,43} Concurrent use of ≥2 CNS active drugs (more with SSRI and TCA) in elderly are associated with risk of falls and fractures.\textsuperscript{3,44}

This study has several limitations. This study findings are based on use of medications in elderly patients admitted in one of the tertiary care teaching Government hospital of India. Due to retrospective study design, we could not assess drug rationality and inter-individual variations in drug selection. We could not identify use of PIM leading to adverse drug reactions due to absence of its documentations in case records.

**CONCLUSION**

PIM are frequently used in the elderly. The commonly used PIM were dextromethorphan, ranitidine, glipizide, spironolactone and dicyclofenac. EU(7) PIM list identifies more number of PIM than Beers criteria in this study population. Clinician should use EU(7) PIM tool in their practice to avoid inappropriate drugs and to find their safer alternative drugs.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Human Ethic Committee, GMERS Medical College, Vadodara, Gujarat, India

**REFERENCES**

1. Davies EA, O’Mahony MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 2015;80(4):796-807.
2. Patel TK, Patel PB. Incidence of Adverse Drug Reactions in Indian Hospitals: A Systematic Review of Prospective Studies. Curr Drug Saf. 2016;11(2):128-36.
3. Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759-70.
4. Laroche ML, Charms JP, Bouthier F, Merle L. Inappropriate medications in the elderly. Clin Pharmacol Ther. 2009;85(1):94-7.
5. Laroche ML, Charms JP, Merle L. Potentially inappropriate medications in the elderly: A French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725-31.
6. Onda M, Imai H, Takada Y, Fujii S, Shono T, Nanaumi Y. Identification and prevalence of adverse drug events caused by potentially inappropriate medication in homebound elderly patients: a retrospective study using a nationwide survey in Japan. BMJ Open. 2015;5(8):e007581.
7. Hyttinen V, Jyrkkä J, Valtonen H. A Systematic Review of the Impact of Potentially Inappropriate Medication on Health Care Utilization and Costs Among Older Adults. Med Care. 2016;54(10):950-64.
8. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening tool of older person's prescriptions) and START (Screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83.
9. Holt S, Schmiedl S, Thürmann PA. Potentially Inappropriate Medications in the Elderly: The PRISCUS List. Dtsch Arztebl Int. 2010;107(31-32):543-51.
10. Renom-Guiteras A1, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75.
11. Lee PCL, Jawad MS, Eccles R. Antitussive Efficacy of Dextromethorphan in Cough Associated with Acute Upper Respiratory Tract Infection. J Pharm Pharmacol. 2000;52(9):1137-42.
12. Storms H, Marquet K, Aertgeerts B, Claes N. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: A systematic review. Eur J Gen Pract. 2017;23(1):69-77.
13. Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S. Prevalence of potentially inappropriate
medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging. 2006;23(10):823-37.
14. Kersten H, Hvidsten LT, Glesers G, Wyller TB, Wang-Hansen MS. Clinical impact of potentially inappropriate medications during hospitalization of acutely ill older patients with multimorbidity. Scand J Prim Health Care. 2015;33(4):243-51.
15. Morandi A, Vasilevsiks E, Pandharipande PP, et al. Inappropriate medication prescriptions in elderly adults surviving an intensive care unit hospitalization. J Am Geriatr Soc. 2013;61(7):1128-34.
16. Morandi A, Vasilevsiks EE, Pandharipande PP, et al. Inappropriate medications in elderly ICU survivors: where to intervene? Arch Intern Med. 2011;171(11):1032-4.
17. Vishwas HN, Harugeri A, Parthasarathi G, Ramesh M. Potentially inappropriate medication use in Indian elderly: comparison of Beers' criteria and Screening Tool of Older Persons' potentially inappropriate Prescriptions. Geriatr Gerontol Int. 2012;12(3):506-14.
18. Jhaiveri BN, Patel TK, Barvaliya MJ, Tripathi C. Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India. Perspect Clin Res. 2014;5(4):184-9.
19. Rawat RS. Evaluation of Potentially Inappropriate Medication Use and Risk of Adverse Drug Reactions in Hospitalized Older Adults: An Observational Study in a Tertiary Care Hospital. Indian J Pharm Pr. 2018;11(2):75-85.
20. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2277-46.
21. Slugg PH, Haug MT 3rd, Pippenger CE. Pippenger. Ramtidrine Pharmacokinetics and Adverse Central Nervous System Reactions. Arch Intern Med. 1992;152(11):2325-9.
22. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20(4):597-606.
23. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491-7.
24. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950-8.
25. Schmidt M, Sorensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018;362:k3426.
26. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care. 2011;56(4):477-87.
27. Ismaila AS, Huisman EL, Punekar YS, Karabis A. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495-517.
28. Singh S, Loke YK, Enright P, Furberg CD. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Postgrad Med J. 2014;90(1062):205-7.
29. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13-9.
30. Mion D Jr, Ortega KC, Gomes MA, Kohlmann O Jr, Oigman W, Nobre F. Amlodipine 2.5 mg once daily in older hypertensives: A Brazilian multi-centre study. Blood Press Monit. 2004;9(2):83-9.
31. Pascual J. Hypertension control in the elderly with amlodipine. Curr Med Res Opin. 2000;16(1):33-6.
32. Owen AJ, Reid CM. Cardio classics revisited: focus on the role of amlodipine. Integr Blood Press Control. 2012;5:1-7.
33. McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509-18.
34. Brett AS. Adverse Effects of Thiazide Diuretics in Older Patients. J Am Geriatr Soc. 2014;62:1039.
35. Gandhi S, McArthur E, Reiss JP, Mamdani MM, Hackam DG, Weir MA, et al. Atypical antipsychotic medications and hyponatraemia in older adults: a population-based cohort study. Can J Kidney Health Dis. 2016;3:21.
36. Meulendijk D, Manesse CK, Jansen PA, van Marum RJ, Egberts TC. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf. 2010;33(2):101-14.
37. Lien YHH. Antidepressants and Hyponatremia. Am J Med. 2018;131(1):7-8.
38. Girouard C, Grégoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine. 2017;96(9):e6239.
39. Inouye SK, Marcantonio ER, Metzger ED. Doing damage in delirium: The Hazards of Antipsychotic Treatment in Elderly persons. Lancet Psychiatry. 2014;1(4):312-5.
40. Kalish VB, Gillham JE, Unwin BK. Delirium in Older Persons: Evaluation and Management. Am Fam Physician. 2014;90(3):150-8.
41. AlagiaKrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80(945):388-93.
42. Chan R, Caplan G. Management of delirium in the elderly. Aust Prescr. 2011;34:63-6.
43. Carrière I, Annie Fourrier-Reglat, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317-24.

44. Masud T, Frost M, Ryg J, Matzen L, Ibsen M, Abrahamsen B, et al. Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA). Age Ageing. 2013;42(1):121-4.

Cite this article as: Thummar MH, Patel TK, Godbole VY, Saurabh MK. Comparison of Beers criteria and EU(7) potentially inappropriate medications list for the potentially inappropriate medications in Indian elderly inpatients. Int J Basic Clin Pharmacol 2019;8:1106-14.